Thus, SB939 in combination with imatinib can result in further enhancement of apoptosis in CML cell lines with the BIM deletion polymorphism (Figs 2B, 2C, 3C and 3E). This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.